Targeting Pim Kinases in Hematological Malignancies.
Eric Gourley(SuperGen (United States)), David J. Bearss(Unknown), Cory L. Grand(SuperGen (United States)), Jeremy Lamb(SuperGen (United States)), Hariprasad Vankayalapati(University of Utah), Xiaohui Liu(Hebei Medical University)
Cited by 1
Related Papers
NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers
|Cancer Cell|2013|302
Paracrine Action of Mesenchymal Stem Cells Revealed by Single Cell Gene Profiling in Infarcted Murine Hearts
|PLoS ONE|2015|93
The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer
|PLoS ONE|2020|82
The mitotic serine threonine kinase, <i>Aurora-2</i>, is a potential target for drug development in human pancreatic cancer
|Molecular Cancer Therapeutics|2004|78
A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel
|Clinical Cancer Research|2016|77